Altinicline (SIB-1508Y SIB-1765F) is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype. It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models and progressed as far as Phase II clinical trials for Parkinson’s disease although its current status is unclear.
This page contains content from the copyrighted Wikipedia article "Altinicline"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
